NeuroGen Pharma

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
CGRP ligandMonoclonal antibody
Migraine
rotigotine(Neupro)
Approved
Dopamine receptorsSmall molecule
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.